51 F
New York
Tuesday, April 20, 2021

Gilead Sciences Inc. [NASDAQ: GILD] Shares Data Regarding HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)

Must read

IAA [NYSE: IAA] Announces Expansion of Delivery Services in the UK

IAA, Inc. disclosed that its UK-based business unit has decided to expand its vehicle delivery services for its buyers. This expansion decision has...

ICON [NASDAQ: ICLR] Secures Multiple Categories in 2021 CRO Leadership Awards

ICON Public Limited Company has disclosed that it has won multiple categories in the annual CRO Leadership Awards. This is another greatest achievement...

Equinox Announces Sale of Pilar Gold Mine

Equinox Gold Corp. revealed Monday that it has decided to sell its Pilar Gold Mine in Brazil to Pilar Gold Inc. The firm...

OpGen [NASDAQ: OPGN] Announces Strategic Collaboration New York State Department of Health

OpGen, Inc. revealed that it has entered into a strategic collaboration deal with the New York State Department of Health. The focus of...

Gilead Sciences Inc. [NASDAQ: GILD] today released data from an ongoing phase 1 study of Lenacapavir (GS-6207). The supporting data disclosed that a novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), maintained treatment for at least six months following a single 900 mg dose.

The study disclosed that the Lenacapavir exhibited no negative effect. Lenacapavir is developed as a component of a long-acting regimen in combination with other antiretroviral agents. Lenacapavir damages the HIV capsid, a multimeric shell that help in viral replication throughout the viral life cycle.

The safety and effectiveness of Lenacapavir were studied in various clinical studies and have not yet been established. Lenacapavir has not gained approval from the US Food and Drug Administration yet and its safety and efficacy are not yet known.

Gilead’s shares traded up 0.38% and up +0.29 during the last trading session of Thursday. It has closed at $76.35. GILD has a gross margin of 79.40%, a profit margin of 21.80%, and an operating margin of 19.60%.

It has day low and day high range of 75.65-76.35, respectively. Gilead Sciences Inc has moved up 25.39% from its 52-weeks low and moved down -11.19% from its 52-weeks high. Its retrun on equity (ROE) is 22.60%, return on assets (ROA) is 8.10% and return on investment (ROI) is 9.50%.

More articles

Latest article

Why Mer Telemanagement [NASDAQ: MTSL] Skyrocketed on Friday?

Shares of Mer Telemanagement Solutions Ltd skyrocketed during the trading session of Friday. The strong performance of the firm has indicated the positive...

Largo Resources Gets Approval for Listing on Nasdaq Stock Exchange

Largo Resources disclosed that it has finally obtained authorization from Nasdaq Stock Market LLC. As per the approval, the firm will now eligible to...

Aurora Mobile [NASDAQ: JG] Inks Agreement with Wanda Film

Aurora Mobile Limited disclosed Thursday that it has inked an agreement with Wanda Film Holding Co Ltd. Since its inception, Aurora Mobile has...

Brady [NYSE: BRC] Commence Tender Offer to Buy Nordic ID Oyj

Brady Corporation has inked an agreement with Nordic ID for its acquisition. The firm has commenced the tender offering to buy all the...

Cinedigm [NASDAQ: CIDM] Achieve Record Subscription and Ad-Supported User Growth Milestones

Shares of Cinedigm Corp. skyrocketed 19.30% after the firm reported the update about the subscription. The firm has achieved the best ever achievement...

Aurora Mobile [NASDAQ: JG] Signs Partnership Agreement with Yivi

Aurora Mobile Limited revealed that it has inked a collaboration deal with Hangzhou Yivi Intelligent Technology Co., LTD. (Yivi). Yivi and Aurora both...

Total [NYSE: TOT] Join Forces with Siemens Energy to Reduce LNG Related Emissions

Total SE has joined forces with Siemens Energy to explore the solution for the reduction of CO2 emissions. The firms have inked a...

Kaixin [NASDAQ: KXIN] Signs Cooperation Agreement with Jingdong

Kaixin Auto Holdings declared Monday that it has inked a deal with Jingdong Century Trade Limited. The agreement is the collaboration agreement between...